Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma
- 28 July 2022
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 72 (2) , 371-384
Abstract
Immune checkpoint inhibitors are effective for advanced hepatocellular carcinoma (HCC), but there remains a need for peripheral blood biomarkers to predict the clinical response. Here, we analyzed the peripheral blood of 45 patients with advanced HCC who underwent nivolumab. During treatment, frequency of classical monocytes (CD14+CD16−) was increased on day 7, and the fold increase in the frequency on day 7 over day 0 (cMonocyteD7/D0) was significantly higher in patients with durable clinical benefit (DCB) than in patients with non-DCB (NDB). When we analyzed transcriptomes of classical monocytes, CD274, gene encoding PD-L1, was upregulated in NDB patients compared to DCB patients at day 7. Notably, gene signature of suppressive tumor-associated macrophages, or IL4l1+PD-L1+IDO1+ macrophages, was enriched after treatment in NDB patients, but not in DCB patients. Accordingly, the fold increase in the frequency of PD-L1+ classical monocytes at day 7 over day 0 (cMonocyte-PDL1D7/D0) was higher in NDB patients than DCB patients. The combined biomarker cMonocyteD7/D0/cMonocyte-PDL1D7/D0 was termed the “monocyte index”, which was significantly higher in DCB patients than NDB patients. Moreover, the monocyte index was an independent prognostic factor for survival. Overall, our results suggest that early changes of circulating classical monocytes, represented as a monocyte index, could predict clinical outcomes of advanced HCC patients undergoing anti-PD-1 therapy.Keywords
Funding Information
- Asan Institute for Life Sciences, Asan Medical Center (2022IP0095, 2018-0634)
- Ministry of Science and ICT, South Korea (NRF-2018M3A9D3079498)
This publication has 47 references indexed in Scilit:
- Cellular and Molecular Identity of Tumor-Associated Macrophages in GlioblastomaCancer Research, 2017
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 responseNature, 2017
- The cellular and molecular origin of tumor-associated macrophagesScience, 2014
- Type I Interferon Suppresses Type II Interferon–Triggered Human Anti-Mycobacterial ResponsesScience, 2013
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisNature, 2011
- Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10Journal of Leukocyte Biology, 2010
- Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 ReceptorsImmunity, 2010
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) MonocytesCancer Research, 2010
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1Journal of Experimental Medicine, 2009
- SOCS3 regulates the plasticity of gp130 signalingNature Immunology, 2003